DailyIQ
|
DailyIQ
|
Last updated1 minute ago

BHVN·Biohaven Ltd.

$13.88
+0.56 (+4.03%)
After Hours
High
$14.58
Open
$14.23
Market Cap
2.30B
52W High
$18.39
Low
$13.17
P. Close
$13.88
P/E
-
52W Low
$7.48
Fwd P/E
-7.45
DailyIQ Est.
$22.45
Inst. Own.
25.4%
Short Interest
10.25%
Days to Cover
9.2
NewEarnings release, scored · filed Oct 29, 2026tone -8.6 vs prior release · 132 lines scoredSee the breakdown
Technical Score (1D)
15
BEARISH
News Sentiment
63
BULLISH
On Nov 5, Biohaven Ltd. reported that enrollment was active in the pivotal Phase 3 trial of its Graves' disease therapy BHV‑1300 and that the company had presented three scientific posters at the 2026 American Thyroid Association Annual Meeting. The company emphasized its continued focus on advancing the BHV‑1300 program and engaging the scientific community to discuss the underlying biology and patient experience. These updates reinforced Biohaven’s position as a leading developer in the autoimmune thyroid disease space and signaled ongoing momentum for the BHV‑1300 pipeline. No other developments were reported for the company on that date.
LOW TARGET
$10 -30.9%
2 analysts
MEAN TARGET
$19 +32.6%
9 analysts
HIGH TARGET
$32 +121.0%
13 analysts
PRICE RANGE
$10.00 - $32.00
SB / B / H / S / SS
7/10/5/1/1
DAILYIQ EST.
$22.45 (+55.0%)
Bought (1Y)
0 shares
$0
Sold (1Y)
0 shares
$0
Gentile KimberlySVP, Clinical Operations
Award/Grant1,000 shares2026-09-15
View full insider trading history →
34/ 100
Bearish
Overall: Bearish
✕Negative operating cash flow
✕High liabilities relative to assets
✓Analyst target above current price
Current Ratio
3.18x
Return on Equity
-1418.8%
View full financials →

EPS

EstBeatMiss
$-1.74$-1.31$-0.88$-0.44$-0.01Q3'25Q3'26Q4'26
QtrEstActual+/−
Q4'26$-0.21 - -
Q3'26$-0.76$-0.86-13.5%
Q3'25$-1.54$-1.47+4.8%

Revenue

EstBeatMiss
$-7M$9M$24M$40M$56MQ3'25Q3'26Q4'26
QtrEstActual+/−
Q4'26$49M - -
Q3'26 - $0 -
Q3'25 - $0 -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

BHVN Stock Snapshot

BEARISH15/100
$13.18−$0.70 (5.0%)
Market cap
2.30B
Day range
$13.17 – $14.58
News sentiment
63/100 · Bullish
Analyst target
$19.20 (+45.7%)
Consensus
Buy · 24 analysts
52-week range+76.2% off low · -28.3% from high
$7.48$18.39
Price $13.18 DailyIQ Est. $22.45

Biohaven Ltd. is trading in the middle of its 52-week range with momentum still pointing lower. Thinner liquidity means moves can extend past what the fundamentals alone justify.

Behaviour On Record

What BHVN's own history says about today's numbers

Realized volatility (21d)
103.6% 86th pct
Below its peak
-75.0%
vs 200-day average
+25.5%
Up days (1y)
45%

Biohaven Ltd. is currently running 103.6% annualised volatility over the last 21 sessions. Measured against BHVN's own 4 years of daily returns rather than a market-wide average, that is the 86th percentile — elevated for this stock, against a typical reading of 69.4%.

BHVN is trading -75.0% below its running peak. Across 4 full years on file, its median worst-drawdown-in-a-year was -43.5%, and the deepest was -82.2% in 2025. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began, and where past declines also continued.

Price sits +25.5% from its 200-day moving average. Against every other day in its history, that gap ranks at the 77th percentile — a somewhat wider gap than its own norm. Over the past year BHVN closed higher on 45% of sessions, and it is currently 1 session into a rising streak.

Overnight risk is measurable too: BHVN has opened more than 2% away from the prior close in 253 of 1,033 sessions (24.5% of the time), with the largest gaps running +9.7% and -19.0%.

All figures computed from 1,034 daily closes between 2022-09-23 and 2026-11-05, split-adjusted, recomputed daily. Percentiles are against BHVN's own 4-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of BHVN's sector?

Biohaven Ltd. sits in the Health Care sector, currently ranked 1st of 12 GICS sectors by relative-strength rotation score (weakening). Within its narrower Biotechnology industry group, BHVN ranks 6th of 15 tracked industries, weakening.

Sector rank
#1 of 12
Sector state
Weakening
Sector rotation score
100
Industry rank
#6 of 15

Options Market

What is the options market pricing for BHVN?

CallsPuts

For Biohaven Ltd.'s nearest expiry (2026-11-20, 13 days out), open interest is put-heavy, a defensive/bearish tilt (put/call ratio of 2.53), with at-the-money implied volatility around 72.5%. The options market is pricing roughly a ±13.1% move by that expiry — a range of about $13.30–$17.30.

Put/call ratio (2026-11-20)
2.53
ATM implied volatility
72.5%
Total open interest
4,500
Expected move by 2026-11-20
±13.1% ($13.30–$17.30)

Analyst Consensus Estimates

What do analysts expect BHVN to earn?

Analysts expect Biohaven Ltd. to earn -$1.76 per share in the fiscal year ending Dec 2026 and -$1.19 in the fiscal year ending Dec 2029, from 3 estimates. These are analyst forecasts, not company guidance, and later years rest on fewer analysts.

Quarter endingEPS estimateEPS rangeEPS analystsRevenue estimateRevenue analysts
Dec 2026-$0.17-$0.67 to $1.556$86M14
Mar 2027-$0.46-$0.46 to -$0.461$12M6
Jun 2027-$0.82-$0.87 to -$0.783--
Sep 2027-$0.46-$0.83 to $0.223--
Fiscal year endingEPS estimateEPS rangeEPS analystsRevenue estimateRevenue analysts
Dec 2026-$1.76-$2.88 to -$0.416$111M14
Dec 2027-$1.79-$2.62 to -$1.216$76M15
Dec 2028-$2.18-$2.44 to -$1.356--
Dec 2029-$1.19-$1.41 to -$0.743--

Analyst Rating Changes

Are analysts turning bullish or bearish on BHVN?

Morgan Stanley most recently reiterated its rating on Biohaven Ltd. to Overweight on Nov 3, 2026 with a price target of $21 (from $19). Over the last 90 days, coverage has run 0 upgrades against 1 downgrade, a net bearish lean.

Latest action
Morgan Stanley: Overweight
90-day upgrades
0
90-day downgrades
1
Net rating momentum
-1
DateFirmActionRatingPrice target
Nov 3, 2026Morgan StanleyMaintainedOverweight$19 → $21
Oct 31, 2026Canaccord GenuityMaintainedBuy$21 → $32
Oct 23, 2026RBC CapitalMaintainedSector Perform$19 → $22
Sep 10, 2026HC Wainwright & Co.ReiteratedNeutral$10
Sep 8, 2026RBC CapitalDowngradeOutperform → Sector Perform$23 → $19
Aug 12, 2026Morgan StanleyMaintainedOverweight$18 → $19
Aug 11, 2026RBC CapitalMaintainedOutperform$22 → $23
Jun 29, 2026B of A SecuritiesDowngradeNeutral → Underperform$12 → $11
May 26, 2026HC Wainwright & Co.ReiteratedNeutral$10
May 13, 2026Morgan StanleyMaintainedOverweight$21 → $18
May 5, 2026RBC CapitalMaintainedOutperform$23 → $22
Apr 2, 2026CitigroupMaintainedBuy$14 → $17

Corporate Stakes

Which companies own a stake in BHVN?

0.29%held by PFE

Pfizer Inc. reports a stake in Biohaven Ltd. on SEC Form 13F: 505.6K shares, about 0.29% of the company, worth $8.0M at the end of Q2 2026. At today's price that stake is worth $6.7M, about 0.00% of PFE's own market value.

Holder
PFE
Shares held
505.6K
Stake
0.29%
Value
$8.0M
HolderLast quarterShares% of BHVNValue at filingValue nowChange
Pfizer Inc. PFEUnchanged505.6K0.29%$8.0M$6.7M-16.7%

Form 13F lists US-listed shares held at quarter-end and is filed up to 45 days later. Stakes in private companies are not on it. Value now and Change put those same shares, adjusted for any stock split, at today's price against their reported quarter-end value, so they do not reflect buying or selling since.

Earnings Release, Scored

What did Biohaven Ltd.'s latest earnings release say?

Filed Oct 29, 2026 · SEC Form 8-K, Exhibit 99

Tone58.2/ 100-8.6 vs prior release
Hedging words0.48per 100 words-0.26 vs prior release
Tone, last 3 releasesScale 50–73

Most important lines

  1. 1

    We are excited to have entered into the first ever regional collaboration for an extracellular protein degrader with Ono Pharmaceutical to develop and commercialize our MoDE IgG degrader portfolio, led by BHV-1300, in Japan, South Korea, Taiwan and the ASEAN region.

    New this quarter
  2. 2

    In October 2026, Biohaven entered into a strategic licensing and collaboration agreement with Ono Pharmaceutical Co., Ltd. (Ono), under which Ono obtained an exclusive license to develop and commercialize Biohaven's MoDE pan IgG degrader portfolio, led by BHV-1300 and including next-generation follow-on degraders BHV-1310 and BHV-1320, in Japan, South Korea, Taiwan and the countries of the Association of Southeast Asian Nations (ASEAN).

    New this quarter
  3. 3

    Opakalim has generally been safe and well tolerated in clinical studies, with more than 1,200 participants dosed to date.

    New this quarter

Scores describe the release's wording. They are not a forecast.

Read all 132 scored lines →

ETF holders

ETFs holding BHVN

Top ETF holdersWeight

News & sentiment

What is the news saying about BHVN?

BHVN rose 20.7% over the month to Nov 6. News tone held between 74 and 92 from Oct 8 to Oct 23, then dropped to 59 on Oct 26.

Daily close and news tone, Oct 6 to Nov 6
$13$15Oct 6Oct 7Oct 8: tone 89Oct 9: tone 92Oct 12Oct 13Oct 14Oct 15Oct 16Oct 19Oct 20Oct 21Oct 22: tone 82Oct 23: tone 74Oct 26: tone 59Oct 27Oct 28Oct 29: tone 73Oct 30: tone 58Nov 2: tone 50Nov 3: tone 61Nov 4Nov 5: tone 63Nov 6Oct 6News toneNov 6123
  1. Oct 22 +28.2%same day: Biohaven stock surges 25% on FDA acceptance of drug filing
  2. Oct 23 -8.2%same day: Biohaven (BHVN) Soars 25% on FDA Drug Review, Price Target Upgrade
  3. Nov 5 -8.8%same day: Biohaven Drives New Research in Graves' Disease: Phase 3 Pivotal Trial with BHV-1300 Underway and Three Scientific Posters at the 2026 American Thyroid Association Annual (ATA) Meeting
Latest stories naming Biohaven

Technical analysis

How strong is BHVN's momentum right now?

On the daily chart BHVN ranks at the 15th percentile for momentum against 1,060 stocks and ETFs, a bearish reading.

Momentum rank by timeframe0 = weakest, 100 = strongest
See what drives the rankThe inputs behind each timeframe's momentum rank, plus RSI, stochastics, Bollinger Bands and moving averages. Free with an account.

Institutional ownership

Are big funds buying or selling BHVN?

34 of the 76 tracked managers added to BHVN in their latest 13F and 31 trimmed. Together they own 25.1% of the company, worth $648.2M. Stifel Financial and Woodline Partners alone hold 10.1%.

34adding31trimming11unchanged
Largest holders by stake, latest 13FBar = share of BHVN
  1. 1Stifel Financial Corp5.69%
    $147.9M positionAdded 0.0% last quarter
  2. 2Woodline Partners LP4.39%
    $114.0M positionAdded 7.4M shares last quarter
  3. 3State Street Corp3.98%
    $103.4M positionAdded 5.0% last quarter
  4. 4UBS Group AG1.44%
    $37.5M positionAdded 76.6% last quarter
  5. 5Vanguard Portfolio Management LLC1.42%
    $37.0M positionAdded 9.2% last quarter
  6. 6Nuveen, LLC1.00%
    $26.0M positionAdded 133.9% last quarter
  7. 7Vanguard Capital Management LLC0.85%
    $22.2M positionAdded 17.2% last quarter
  8. 8BNP Paribas Financial Markets0.70%
    $18.2M positionTrimmed 20.7% last quarter
  9. 9Charles Schwab Investment Management Inc0.64%
    $16.5M positionAdded 17.9% last quarter
  10. 10Qube Research & Technologies Ltd0.52%
    $13.5M positionTrimmed 41.2% last quarter
Full holdings history

Discover more

How has BHVN done against its peers?

Over the six months to Nov 6, BHVN returned +45.8%. Of the 15 related stocks and ETFs, 2 did better, led by MRNA at +418.9%.

Change since May 6, through Nov 6
−200%0%+200%+400%+600%May 6JunJulAugSepOctNov 6MRNA +418.9%BHVN +45.8%INSM −18.2%